Payment overview · 2025
General Payments
$252.36
14 reported records · 8 companies
Healthcare provider profile · identity verified
James L Walker, N.P.
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · STATESBORO, GA · NPI 1134149313
Verified facts
What the public records show
CMS Open Payments records show James L Walker, N.P. received $252.36 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.35 | 25.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.11 | 20.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.96 | 14.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.00 | 12.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.15 | 7.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.08 | 7.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.90 | 6.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.81 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $252.36 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.62 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.76 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.96 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 336 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 310 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 298 | 73 |
| Gabapentin | Gabapentin | 269 | 55 |
| Tramadol Hcl | Tramadol Hcl | 262 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 51 |
| Famotidine | Famotidine | 239 | 45 |
| Lisinopril | Lisinopril | 221 | 49 |
| Potassium Chloride | Potassium Chloride | 199 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 44 |
| Omeprazole | Omeprazole | 193 | 51 |
| Meloxicam | Meloxicam | 188 | 42 |
| Furosemide | Furosemide | 169 | 39 |
| Metformin Hcl | Metformin Hcl | 169 | 42 |
| Alprazolam | Alprazolam | 153 | 25 |
| Losartan Potassium | Losartan Potassium | 143 | 37 |
| Trazodone Hcl | Trazodone Hcl | 134 | 35 |
| Clonazepam | Clonazepam | 133 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 119 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 19 |
| Eliquis | Apixaban | 103 | 19 |
| Simvastatin | Simvastatin | 103 | 23 |
| Carvedilol | Carvedilol | 98 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 19 |
| Allopurinol | Allopurinol | 91 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 23 |
| Prednisone | Prednisone | 91 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | 15 |
| Montelukast Sodium | Montelukast Sodium | 87 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 80 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 23 |
| Ozempic | Semaglutide | 74 | 11 |
| Sertraline Hcl | Sertraline Hcl | 73 | 19 |
| Celecoxib | Celecoxib | 71 | 20 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 70 | suppressed |
| Lorazepam | Lorazepam | 70 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 15 |
| Pregabalin | Pregabalin | 66 | suppressed |
| Azithromycin | Azithromycin | 64 | 52 |
| Amoxicillin | Amoxicillin | 59 | 52 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 38 |
| Meclizine Hcl | Meclizine Hcl | 58 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 43 |
| Jardiance | Empagliflozin | 54 | suppressed |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 22 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 49 | 16 |
| Estradiol | Estradiol | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 46 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 12 |
| Temazepam | Temazepam | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 13 |
| Ezetimibe | Ezetimibe | 42 | suppressed |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 11 |
| Dutasteride | Dutasteride | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Baclofen | Baclofen | 32 | 11 |
| Fluconazole | Fluconazole | 32 | 24 |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 26 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 23 |
| Ketoconazole | Ketoconazole | 28 | 18 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 12 |
| Naproxen | Naproxen | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Diazepam | Diazepam | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $252.36 · 14 records | ABBVIE INC. | AIRSUPRA, Auvelity, FARXIGA, MOUNJARO, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error